Clinical application of annual Liver Multiscan and MRCP+ in Primary Sclerosing Cholangitis:

Clinical application of annual Liver Multiscan and MRCP+ in Primary Sclerosing Cholangitis: - CATCH-IT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53990

Enrollment

200

Registered

2023-04-18

Start date

2023-07-21

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Sclerosing Cholangitis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Established diagnosis according to the IPSCSG Definitions (26) Age >= 18 Able to give informed consent

Exclusion criteria

Exclusion criteria: Known allergy for MRI contrast agents, implants non-compatible with MRI or extreme claustrophobia causing discontinuation of MRI studies. Post livertransplantation

Design outcomes

Primary

Measure	Time frame
Delta of cT1 in patients with PSC during follow-up	—

Secondary

Measure	Time frame
Mean, median and range of cT1 and MRCP+ metrics in clinically and biochemically stable patients Variance of the delta in cT1 and MRCP+ metrics from baseline to year 1 in clinically and biochemically stable patients Difference in mean of cT1 values in patients who needed ERCP with treatment of dominant stricture(s) in the year following LMS measurement versus those who did not need an intervention Variance of the delta of cT1 and MRCP+ metrics in sequential scans in biochemically and/or clinically deteriorating patients. Correlation between cT1 and MRCP+ metrics with Fibroscan and MELD-score Correlation between cT1 and MRCP+ metrics and development of dominant strictures Correlation between cT1 and MRCP+ metrics and incidence of CCA	—

Measure

Time frame

Mean, median and range of cT1 and MRCP+ metrics in clinically and biochemically stable patients Variance of the delta in cT1 and MRCP+ metrics from baseline to year 1 in clinically and biochemically stable patients Difference in mean of cT1 values in patients who needed ERCP with treatment of dominant stricture(s) in the year following LMS measurement versus those who did not need an intervention Variance of the delta of cT1 and MRCP+ metrics in sequential scans in biochemically and/or clinically deteriorating patients. Correlation between cT1 and MRCP+ metrics with Fibroscan and MELD-score Correlation between cT1 and MRCP+ metrics and development of dominant strictures Correlation between cT1 and MRCP+ metrics and incidence of CCA

—

Countries

Netherlands

Outcome results